In a pair of studies on NSCLC cells, we have confirmed the inhibitory effect of cilengitide co-administration and the EGFR inhibitor gefitinib [36] or erlotinib (the current work) on EMT. Here, EGFR is linked to non-small cell lung carcinoma.